Strides Pharma Science Ltd Posts Strong Q1 Results for FY 2026 with Focus on Niche Formulations and Global Expansion
Strides Pharma Science Ltd has reported a strong first quarter for FY 2026, with revenue of Rs. 11,197 million and operational PAT of Rs. 1,140 million, driven by its strategic focus on niche pharmaceuticals and global reach.
2 minutes to read